1d
GlobalData on MSNGilead’s lenacapavir applications for HIV gain EMA validationThe latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ: GILD )' Lenacapavir (LEN) for HIV ...
Operatives working for Elon Musk’s DOGE appear to be editing the code of AutoRIF—software designed by the Defense Department ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results